Videos

At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.

At AAO 2024, Khanani discussed data showing a 97% reduction in annualized injection needs at 9 months with RGX-314 gene therapy.

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

In the most recent Lungcast, Rachel Eddy, PhD, joined host Al Rizzo, MD, to speak to listeners about the current and future uses of AI in lung imaging.

At AAO 2024, Pearlman discusses how an innovative oral approach may provide an alternative pathway to existing treatments for DME.

At AAO 2024, Goldberg described pooled visual function data from 3 randomized, controlled clinical trials evaluating NT-501 for patients with MacTel.

At AAO 2024, Borkar discusses the visual acuity benefit of ONL1204 ophthalmic solution for patients with macula-off rhegmatogenous retinal detachment.

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

At AAO 2024, Cunningham describes the clinical response and safety of faricimab (Vabysmo) in underrepresented populations with diabetic macular edema.

In part 2 of this 3-part series, Sperling and Gianos highlight the role of lipoprotein apheresis in contemporary settings and the supporting evidence base.

Laurence Sperling, MD, and Eugenia Gianos, MD, discuss the historical context and underutilization of lipoprotein apheresis in part 1 of a 3-part video series.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.

HCPLive spoke with Monroe regarding muscarinic modulators, both the ones in development and xanomeline trospium chloride capsules (Cobenfy).

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from Maui Derm NP+PA Fall 2024 in Nashville.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.

Benjamin Scirica, MD, discusses the importance of team-based care and leveraging technology to optimize the management of cardiovascular risk factors.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

Del Rosso reviews several key highlights from his Maui Derm presentation on acne and rosacea updates from 2024.